Literature DB >> 23986398

Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.

Surender Khurana1, Crystal L Loving, Jody Manischewitz, Lisa R King, Phillip C Gauger, Jamie Henningson, Amy L Vincent, Hana Golding.   

Abstract

Vaccine-induced disease enhancement has been described in connection with several viral vaccines in animal models and in humans. We investigated a swine model to evaluate mismatched influenza vaccine-associated enhanced respiratory disease (VAERD) after pH1N1 infection. Vaccinating pigs with whole inactivated H1N2 (human-like) virus vaccine (WIV-H1N2) resulted in enhanced pneumonia and disease after pH1N1 infection. WIV-H1N2 immune sera contained high titers of cross-reactive anti-pH1N1 hemagglutinin (HA) antibodies that bound exclusively to the HA2 domain but not to the HA1 globular head. No hemagglutination inhibition titers against pH1N1 (challenge virus) were measured. Epitope mapping using phage display library identified the immunodominant epitope recognized by WIV-H1N2 immune sera as amino acids 32 to 77 of pH1N1-HA2 domain, close to the fusion peptide. These cross-reactive anti-HA2 antibodies enhanced pH1N1 infection of Madin-Darby canine kidney cells by promoting virus membrane fusion activity. The enhanced fusion activity correlated with lung pathology in pigs. This study suggests a role for fusion-enhancing anti-HA2 antibodies in VAERD, in the absence of receptor-blocking virus-neutralizing antibodies. These findings should be considered during the evaluation of universal influenza vaccines designed to elicit HA2 stem-targeting antibodies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23986398     DOI: 10.1126/scitranslmed.3006366

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  107 in total

1.  Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014.

Authors:  Nancy J Cox; Julian Hickling; Rebecca Jones; Guus F Rimmelzwaan; Linda C Lambert; John Boslego; Larisa Rudenko; Leena Yeolekar; James S Robertson; Joachim Hombach; Justin R Ortiz
Journal:  Vaccine       Date:  2015-10-23       Impact factor: 3.641

Review 2.  Progress on adenovirus-vectored universal influenza vaccines.

Authors:  Kui Xiang; Guan Ying; Zhou Yan; Yan Shanshan; Zhang Lei; Li Hongjun; Sun Maosheng
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Bringing influenza vaccines into the 21st century.

Authors:  Ethan C Settembre; Philip R Dormitzer; Rino Rappuoli
Journal:  Hum Vaccin Immunother       Date:  2013-12-30       Impact factor: 3.452

4.  Universal influenza virus vaccines: need for clinical trials.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Immunol       Date:  2014-01       Impact factor: 25.606

5.  Vaccines for pandemics.

Authors:  Charles Schmidt
Journal:  Nat Biotechnol       Date:  2013-11       Impact factor: 54.908

Review 6.  Fast vaccine design and development based on correlates of protection (COPs).

Authors:  Cécile van Els; Siri Mjaaland; Lisbeth Næss; Julia Sarkadi; Eva Gonczol; Karen Smith Korsholm; Jon Hansen; Jørgen de Jonge; Gideon Kersten; Jennifer Warner; Amanda Semper; Corine Kruiswijk; Fredrik Oftung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures in Human Peripheral Blood Mononuclear Cells.

Authors:  Leigh M Howard; Johannes B Goll; Travis L Jensen; Kristen L Hoek; Nripesh Prasad; Casey E Gelber; Shawn E Levy; Sebastian Joyce; Andrew J Link; C Buddy Creech; Kathryn M Edwards
Journal:  J Infect Dis       Date:  2019-05-05       Impact factor: 5.226

8.  Increased influenza-specific antibody avidity in HIV-infected women compared with HIV-infected men on antiretroviral therapy.

Authors:  Zhenwu Luo; Elizabeth Ogunrinde; Min Li; Lumin Zhang; Lisa Martin; Zejun Zhou; Zhiliang Hu; Tao Zhang; Zhen Li; Jiafeng Zhang; Bin Su; Tong Zhang; Hao Wu; Lei Ma; Guoyang Liao; Allison Ross Eckard; Maria Anna Julia Westerink; Sonya L Heath; Wei Jiang
Journal:  AIDS       Date:  2019-01-27       Impact factor: 4.177

9.  Substitutions near the hemagglutinin receptor-binding site determine the antigenic evolution of influenza A H3N2 viruses in U.S. swine.

Authors:  Nicola S Lewis; Tavis K Anderson; Pravina Kitikoon; Eugene Skepner; David F Burke; Amy L Vincent
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

Review 10.  A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza.

Authors:  Boopathy Ramakrishnan; Karthik Viswanathan; Kannan Tharakaraman; Vlado Dančík; Rahul Raman; Gregory J Babcock; Zachary Shriver; Ram Sasisekharan
Journal:  Trends Microbiol       Date:  2016-10-14       Impact factor: 17.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.